Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines

Applied Microbiology and Biotechnology

Volumn 89, Issue 5, 2011, Pages 1423-1433

  Lu, Xiao Yun ^a,b   Ciraolo, Elisa ^b   Stefenia, Rachele ^b   Chen, Guo Qiang ^c   Zhang, Yali ^a   Hirsch, Emilio ^a,b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TURIN   (Italy)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

Drug delivery; Nanoparticle; PI3K inhibitor; Polyhydroxyalkanoate; TGX221

Indexed keywords

CANCER CELL GROWTH; CANCER CELL LINES; CANCER MODELS; CANCER TREATMENT; CLEARANCE RATES; COMMON FEATURES; EXTRACELLULAR STIMULI; HIGH POTENCY; HUMAN CANCER; HYDROXYL GROUPS; IN-CELL; IN-VITRO; IN-VIVO; LIPID KINASE; NEGATIVE CONTROL; NEW STRATEGY; PHOSPHOINOSITIDES; PI3K INHIBITOR; POLY-HYDROXYALKANOATE; SUSTAINED RELEASE; TGX221;

BIOCHEMISTRY; CELL CULTURE; CELLS; DRUG DELIVERY; DRUG PRODUCTS; ENZYMES; GROWTH KINETICS; NANOPARTICLES; PLASMA DIAGNOSTICS; PLASMA STABILITY;

DISEASES;

9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; DRUG CARRIER; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYHYDROXYALKANOIC ACID; UNCLASSIFIED DRUG;

BIOAVAILABILITY; CANCER; DRUG; GROWTH REGULATOR; INHIBITOR; NANOTECHNOLOGY; SOLUBILITY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN BT 474; CELL STRAIN HCT116; CELL STRAIN PC3; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG RELEASE; DRUG SELECTIVITY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TUMOR GROWTH; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; ENZYME INHIBITORS; HUMANS; MORPHOLINES; NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASES; POLYHYDROXYALKANOATES; PYRIMIDINONES;

ANIMALIA;

EID: 79952574593     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-011-3101-1     Document Type: Article

References (37)

1. Bader AG, Kang SY, Zhao L, Vogt PK (2005) Oncogenic pi3k deregulates transcription and translation. Nat Rev Cancer 5 (12):921-929. doi:10.1038/nrc1753 (Pubitemid 41766781)
2. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Gronning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR (2007) Evidence for functional redundancy of class ia pi3k isoforms in insulin signalling. Biochem J 404:449-458. doi:10.1042/bj20070003 (Pubitemid 46953919)
3. Cheng S, Wu Q, Yang F, Xu M, Leski M, Chen GQ (2005) Influence of dl-beta-hydroxybutyric acid on cell proliferation and calcium influx. Biomacromolecules 6(2):593-597. doi:10.1021/bm049465y (Pubitemid 40467798)
4. Cheng S, Chen GQ, Leski M, Zou B, Wang Y, Wu Q (2006) The effect of d, l-beta-hydroxybutyric acid on cell death and proliferation in l929 cells. Biomaterials 27(20):3758-3765. doi:10.1016/j.biomaterials.2006.02.046
5. Chin L, Meyerson M, Aldape K, Bigner D, Mikkelsen T, VandenBerg S, Kahn A, Penny R, Ferguson ML, Gerhard DS, Getz G, Brennan C, Taylor BS, Winckler W, Park P, Ladanyi M, Hoadley KA, Verhaak RGW, Hayes DN, Spellman PT, Absher D, Weir BA, Ding L, Wheeler D, Lawrence MS, Cibulskis K, Mardis E, Zhang JH, Wilson RK, Donehower L, Wheeler DA, Purdom E, Wallis J, Laird PW, Herman JG, Schuebel KE, Weisenberger DJ, Baylin SB, Schultz N, Yao J, Wiedemeyer R, Weinstein J, Sander C, Gibbs RA, Gray J, Kucherlapati R, Lander ES, Myers RM, Perou CM, McLendon R, Friedman A, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Lehman N, Yung WKA, Bogler O, Berger M, Prados M, Muzny D, Morgan M, Scherer S, Sabo A, Nazareth L, Lewis L, Hall O, Zhu YM, Ren YR, Alvi O, Yao JQ, Hawes A, Jhangiani S, Fowler G, San Lucas A, Kovar C, Cree A, Dinh H, Santibanez J, Joshi V, Gonzalez-Garay ML, Miller CA, Milosavljevic A, Sougnez C, Fennell T, Mahan S, Wilkinson J, Ziaugra L, Onofrio R, Bloom T, Nicol R, Ardlie K, Baldwin J, Gabriel S, Fulton RS, McLellan MD, Larson DE, Shi XQ, Abbott R, Fulton L, Chen K, Koboldt DC, Wendl MC, Meyer R, Tang YZ, Lin L, Osborne JR, Dunford-Shore BH, Miner TL, Delehaunty K, Markovic C, Swift G, Courtney W, Pohl C, Abbott S, Hawkins A, Leong S, Haipek C, Schmidt H, Wiechert M, Vickery T, Scott S, Dooling DJ, Chinwalla A, Weinstock GM, O'Kelly M, Robinson J, Alexe G, Beroukhim R, Carter S, Chiang D, Gould J, Gupta S, Korn J, Mermel C, Mesirov J, Monti S, Nguyen H, Parkin M, Reich M, Stransky N, Garraway L, Golub T, Protopopov A, Perna I, Aronson S, Sathiamoorthy N, Ren G, Kim H, Kong SK, Xiao YH, Kohane IS, Seidman J, Cope L, Pan F, Van Den Berg D, Van Neste L, Yi JM, Li JZ, Southwick A, Brady S, Aggarwal A, Chung T, Sherlock G, Brooks JD, Jakkula LR, Lapuk AV, Marr H, Dorton S, Choi YG, Han J, Ray A, Wang V, Durinck S, Robinson M, Wang NJ, Vranizan K, Peng V, Van Name E, Fontenay GV, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Socci ND, Olshen A, Lash A, Reva B, Antipin Y, Stukalov A, Gross B, Cerami E, Wang WQ, Qin LX, Seshan VE, Villafania L, Cavatore M, Borsu L, Viale A, Gerald W, Topal MD, Qi Y, Balu S, Shi Y, Wu G, Bittner M, Shelton T, Lenkiewicz E, Morris S, Beasley D, Sanders S, Sfeir R, Chen J, Nassau D, Feng L, Hickey E, Schaefer C, Madhavan S, Buetow K, Barker A, Vockley J, Compton C, Vaught J, Fielding P, Collins F, Good P, Guyer M, Ozenberger B, Peterson J, Thomson E, Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068. doi:10.1038/nature07385
6. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu HY, Dastru W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Ruckle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E (2008) Phosphoinositide 3-kinase p110 beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 1(36). doi:10.1126/scisignal.1161577
7. Gursel I, Korkusuz F, Turesin F, Alaeddinoglu NG, Hasirci V (2001) In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 22(1):73-80
8. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan YP, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH (2005) Pi 3-kinase p110 beta: a new target for antithrombotic therapy. Nat Med 11(5):507-514. doi:10.1038/nm1232 (Pubitemid 40685973)
9. Jeong I, Kim BS, Lee H, Lee KM, Shim I, Kang SK, Yin CS, Hahm DH (2009) Prolonged analgesic effect of PLGA-encapsulated bee venom on formalin-induced pain in rats. Int J Pharm 380(1-2):62-66. doi:10.1016/j.ijpharm.2009.06.034
10. Ji Y, Li XT, Chen GQ (2008) Interactions between a poly(3- hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate) terpolyester and human keratinocytes. Biomaterials 29(28):3807-3814. doi:10.1016/j.biomaterials. 2008.06.008
11. Keniry M, Parsons R (2008) The role of pten signaling perturbations in cancer and in targeted therapy. Oncogene 27(41):5477-5485. doi:10.1038/onc.2008. 248
12. Koosha F, Muller RH, Davis SS (1989) Polyhydroxybutyrate as a drug carrier. Crit Rev Ther Drug Carr Syst 6(2):117-130 (Pubitemid 19270116)
13. Kueng W, Silber E, Eppenberger U (1989) Quantification of cells cultured on 96-well plates. Anal Biochem 182(1):16-19 (Pubitemid 19251274)
14. Langer R (1998) Drug delivery and targeting. Nature 392(6679):5-10
15. Leevers SJ, Vanhaesebroeck B, Waterfield MD (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 11(2):219-225 (Pubitemid 29164037)
16. Li Q, Wang Y, Feng NP, Fan ZZ, Sun J, Nan YL (2008) Novel polymeric nanoparticles containing tanshinone IIa for the treatment of hepatoma. J Drug Target 16(10):725-732. doi:10.1080/10611860802374303
17. Liu Q, Chen GQ (2008) In vitro biocompatibility and degradation of terpolyester 3hb-co-4hb-co-3hhx, consisting of 3-hydroxybutyrate, 4-hydroxybutyrate and 3-hydroxyhexanoate. J Biomater Sci Polym Ed 19(11):1521-1533
18. Liu PX, Cheng HL, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627-644. doi:10.1038/nrd2926
19. Lu XY, Zhang YL, Wang L (2010) Preparation and in vitro drug-release behavior of 5-fluorouracil-loaded poly(hydroxybutyrateco-hydroxyhexanoate) nanoparticles and microparticles. J Appl Polym Sci 116(5):2944-2950. doi:10.1002/app.31806
20. Muller RH, Maassen S, Weyhers H, Specht F, Lucks JS (1996) Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm 138(1):85-94 (Pubitemid 26241925)
21. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J Control Release 125(3):193-209. doi:10.1016/j.jconrel.2007.09.013
22. Parsons DW, Jones S, Zhang XS, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321 (5897):1807-1812. doi:10.1126/science.1164382
23. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ (2001) Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 75 (1-2):211-224 (Pubitemid 32635211)
24. Rossi S, Azghani AO, Omri A (2004) Antimicrobial efficacy of a new antibiotic-loaded poly(hydroxybutyric-co-hydroxyvaleric acid) controlled release system. J Antimicrob Chemother 54(6):1013-1018. doi:10.1093/jac/dkh477 (Pubitemid 40136733)
25. Saad B, Ciardelli G, Matter S, Welti M, Uhlschmid GK, Neuenschwander P, Suter UW (1996a) Cell response of cultured macrophages, fibroblasts, and co-cultures of Kupffer cells and hepatocytes to particles of short-chain poly (r)-3-hydroxybutyric acid. J Mater Sci Mater Med 7(1):56-61 (Pubitemid 26044853)
26. Saad B, Ciardelli G, Matter S, Welti M, Uhlschmid GK, Neuenschwander P, Suter UW (1996b) Characterization of the cell response of culturedmacrophages and fibroblasts to particles of short-chain poly (r)-3-hydroxybutyric acid. J Biomed Mater Res 30(4):429-439 (Pubitemid 26107076)
27. Shi JJ, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10(9):3223-3230. doi:10.1021/nl102184c
28. Steinbuchel A (2001) Perspectives for biotechnological production and utilization of biopolymers: metabolic engineering of polyhydroxyalkanoate biosynthesis pathways as a successful example. Macromol Biosci 1(1):1-24
29. Sun J, Dai ZW, Zhao Y, Chen GQ (2007) In vitro effect of oligohydroxyalkanoates on the growth of mouse fibroblast cell line l929. Biomaterials 28(27):3896-3903. doi:10.1016/j.biomaterials.2007.05.011
30. Thomas RK, Baker AC, DeBiasi RM, Winckler W, LaFramboise T, Lin WM, Wang M, Feng W, Zander T, MacConnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351. doi:10.1038/ng1975 (Pubitemid 46328493)
31. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22(7):267-272 (Pubitemid 27310948)
32. Wang ZX, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I, Umeda F, Yamakawa J, Kawase M, Yagi K (2003) Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng 95(5):541-543 (Pubitemid 36688182)
33. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, DeBeaumont R, Stegmeier F, Yao YM, Lengauer C (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 105 (35):13057-13062. doi:10.1073/pnas.0802655105
34. Wu Q, Wang Y, Chen GQ (2009) Medical application of microbial biopolyesters polyhydroxyalkanoates. Artif Cells Blood Substit Immobil Biotechnol 37(1):1-12. doi:10.1080/10731190802664429
35. Xiao XQ, Zhao Y, Chen GQ (2007) The effect of 3-hydroxybutyrate and its derivatives on the growth of glial cells. Biomaterials 28 (25):3608-3616. doi:10.1016/j.biomaterials.2007.04.046 (Pubitemid 46855879)
36. Xiong YC, Yao YC, Zhan XY, Chen GQ (2010) Application of polyhydroxyalkanoates nanoparticles as intracellular sustained drug-release vectors. J Biomater Sci Polym Ed 21(1):127-140. doi:10.1163/156856209x410283
37. Yao YC, Zhan XY, Zhang J, Zou XH, Wang ZH, Xiong YC, Chen J, Chen GQ (2008) A specific drug targeting system based on polyhydroxyalkanoate granule binding protein phap fused with targeted cell ligands. Biomaterials 29(36):4823-4830. doi:10.1016/j.biomaterials.2008.09.008